Prexton Therapeutics Report issue

For profit Phase 2
Founded: Plan-les-ouates Switzerland (2012)
Status: Acquired by Lundbeck (2018)

Organization Overview

First Clinical Trial
2016
NCT02639221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prexton Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

foliglurax (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyskinesias (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1